Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncolytic Adenovirus Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for oncolytic adenovirus has witnessed considerable growth lately. It’s projected to rise from $122.31 billion in 2024 to $132.49 billion in 2025, registering a compound annual growth rate (CAGR) of 8.3%. The growth witnessed in the historical period is due to a surge in cancer cases, augmented demand for tailored cancer treatments, an increase in R&D funds, enhancement in delivery procedures, and regulatory approvals.

With a robust increase projected over the coming years, the oncolytic adenovirus market is anticipated to surge to$181.71 billion by 2029 at an 8.2% compound annual growth rate (CAGR). The substantial growth anticipated during this period is attributed to factors such as rising instances and prevalence of cancer, the extension of combination therapies, advancements and approvals in regulations, breakthroughs in virus engineering technology, as well as heightened investment in oncology research. The main trends forecasted during this period involve progresses in viral engineering methodologies, enhanced drug delivery systems, precision improvements in tumor targeting, superior combinations of immunotherapy, and advancements in patient monitoring and diagnostic procedures.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Oncolytic Adenovirus Market?

The relentless rise in cancer cases is set to further stimulate expansion in the oncolytic adenovirus market. This illness, defined by unregulated cell proliferation and dissemination to other body sites, has seen its prevalence escalate due to aging populations, lifestyle choices, environmental exposure, genetic predispositions, and superior detection techniques. Oncolytic adenoviruses specifically target and annihilate cancer cells, presenting a hopeful strategy to counter the mounting number of cancer incidents. For instance, reports released by the National Cancer Institute (NCI), a US governmental body, in May 2024 stated that the world witnessed nearly 20 million fresh cancer cases and 9.7 million fatalities, with a forecast for 2040 to burgeon to approximately 29.9 million cases and 15.3 million deaths. Moreover, statistics from the Australian Bureau of Statistics, a government agency in Australia, showed in 2023 that 1.8% of Australians were diagnosed with cancer, with a slightly higher proportion of men (2.1%) than women (1.6%) being afflicted, particularly those aged 75 and over. Consequently, the escalating occurrence of cancer is propelling the growth trajectory of the oncolytic adenovirus market.

Which Key Market Segments Comprise the Oncolytic Adenovirus Market and Drive Its Revenue Growth?

The oncolytic adenovirusmarket covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types

2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications

3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Which Areas Are Leading Regions in the Oncolytic Adenovirus Market Expansion Across the Globe?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theOncolytic Adenovirus Market Over the Coming Years?

Dominant businesses in the oncolytic adenovirus market are concentrating on collaborative therapies such as VCN-01. This method merges oncolytic virotherapy and chemotherapy to enhance tumor targeting and amplify therapeutic results. VCN-01 is a purposefully engineered oncolytic adenovirus that aims to selectively infect and eliminate cancer cells while also boosting the efficiency of chemotherapy. In May 2024, for instance, Theriva Biologics, a clinical-phase immuno-oncology business located in the United States, reported that the U.S. Food and Drug Administration (FDA) conferred Fast Track Designation (FTD) to their leading candidate, VCN-01. This title is applied to VCN-01 when used alongside gemcitabine and nab-paclitaxel for handling metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and multiplies within tumor cells, assisting in the tumor stroma breakdown, a significant barrier to successful cancer therapy.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

How Is the Oncolytic Adenovirus Market Conceptually Defined?

Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model